Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Johnson and Johnson
Medtronic
Harvard Business School
Boehringer Ingelheim

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR MYLOTARG


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Mylotarg

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006265 ↗ Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed National Cancer Institute (NCI) Phase 2 2001-03-01 RATIONALE: Monoclonal antibodies, such as gemtuzumab ozogamicin, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining gemtuzumab ozogamicin with cytarabine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining gemtuzumab ozogamicin with high-dose cytarabine in treating patients who have relapsed or refractory acute myeloid leukemia.
NCT00006265 ↗ Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed Alliance for Clinical Trials in Oncology Phase 2 2001-03-01 RATIONALE: Monoclonal antibodies, such as gemtuzumab ozogamicin, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining gemtuzumab ozogamicin with cytarabine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining gemtuzumab ozogamicin with high-dose cytarabine in treating patients who have relapsed or refractory acute myeloid leukemia.
NCT00017589 ↗ Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia Completed Genta Incorporated Phase 2 2000-12-01 RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab ozogamicin in treating older patients who have relapsed acute myeloid leukemia.
NCT00038805 ↗ Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) Terminated Wyeth is now a wholly owned subsidiary of Pfizer Phase 2/Phase 3 2001-05-01 Primary Objective: To determine the safety and maximum tolerated dose of CMA-676 as part of an intensive but nonmyeloablative preparative regimen in older or medically infirm patients undergoing mini-allogeneic peripheral blood stem cell transplantation Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate disease-free and overall survival and relapse rates. 3. To evaluate the need and ability to give multiple cycles of Mylotarg plus FA and mobilized DLI in patients not achieving complete remission.
NCT00038805 ↗ Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) Terminated M.D. Anderson Cancer Center Phase 2/Phase 3 2001-05-01 Primary Objective: To determine the safety and maximum tolerated dose of CMA-676 as part of an intensive but nonmyeloablative preparative regimen in older or medically infirm patients undergoing mini-allogeneic peripheral blood stem cell transplantation Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate disease-free and overall survival and relapse rates. 3. To evaluate the need and ability to give multiple cycles of Mylotarg plus FA and mobilized DLI in patients not achieving complete remission.
NCT00038831 ↗ Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS Completed M.D. Anderson Cancer Center Phase 1/Phase 2 2001-05-01 The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation. Researchers will study the effects of this treatment combination on patients with high-risk acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome. Primary Objective: 1. To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation. Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate the incidence and severity of GVHD in this population 3. To evaluate disease-free and overall survival and relapse rates.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mylotarg

Condition Name

Condition Name for Mylotarg
Intervention Trials
Acute Myeloid Leukemia 19
Leukemia 11
Myelodysplastic Syndrome 9
Acute Myelogenous Leukemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mylotarg
Intervention Trials
Leukemia 52
Leukemia, Myeloid, Acute 50
Leukemia, Myeloid 47
Myelodysplastic Syndromes 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mylotarg

Trials by Country

Trials by Country for Mylotarg
Location Trials
United States 284
Canada 24
Spain 17
Germany 6
France 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mylotarg
Location Trials
Texas 17
New York 13
California 13
Washington 12
North Carolina 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mylotarg

Clinical Trial Phase

Clinical Trial Phase for Mylotarg
Clinical Trial Phase Trials
Phase 4 3
Phase 3 8
Phase 2/Phase 3 3
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mylotarg
Clinical Trial Phase Trials
Completed 24
Recruiting 21
Active, not recruiting 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mylotarg

Sponsor Name

Sponsor Name for Mylotarg
Sponsor Trials
National Cancer Institute (NCI) 23
Pfizer 12
M.D. Anderson Cancer Center 10
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mylotarg
Sponsor Trials
Other 65
Industry 25
NIH 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Express Scripts
Moodys
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.